Pokaż cały numer - FPN - Farmaceutyczny Przegląd Naukowy
Share Embed Flag
Download ePaper

Pokaż cały numer - FPN - Farmaceutyczny Przegląd Naukowy

Pokaż cały numer - FPN - Farmaceutyczny Przegląd Naukowy Pokaż cały numer - FPN - Farmaceutyczny Przegląd Naukowy

fpn.sum.edu.pl
from fpn.sum.edu.pl More from this publisher
29.11.2014 Views

Farm Przegl Nauk, 2010, 12 17. Wise S, Chien J, Yeo K, Richardson C. Smoking enhances absorption of insulin but reduces glucodynamic effects in individuals using the Lilly-Dura inhaled insulin system. Diabet Med 2006; 23: 510-515. 18. Chaudhuri R i wsp. Cigarette smoking impairs the therapeutic response to oral corticosteroids in chronic asthma. Am J Respir Crit Care Med 2003; 168: 1308-1311. 19. Byron KA, Varigos GA, Wootton AM. IL-4 production is increased in cigarette smokers. Clin Exp Immunol 1994; 95: 333-336. 20. Thomson NC, Spears M. The influence of smoking on the treatment response in patients with asthma. Curr Opin Allergy Clin Immunol 2005; 5: 57-63. 21. Tomlinson JEM. Efficacy of low and high dose inhaled corticosteroid in smokers versus non-smokers with mild asthma. Thorax 2005; 60: 282-287. 22. Invernizzi G i wsp. Inhaled steroid/tobacco smoke particle interactions: a new light on steroid resistance. Respir Res 2009; 10: 48. 23. Chalmers GW i wsp. Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax 2002; 57: 226-230. 24. Perry P i wsp. Relationship between variables and plasma clozapine concentrations: a dosing nomogram. Biol Psychiatry 1998; 44: 733-738. 25. Berecz R. Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype. Eur J Clin Pharmacol 2003; 59: 45-50. 26. Ohara K i wsp. Effects of smoking and cytochrome P450 2D6*10 allele on the plasma haloperidol concentration/dose ratio. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 945-949. 27. Spigset O i wsp. Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans. Clin Pharmacol Ther 1995; 58: 399-403. 28. Gerstenberg G i wsp. Effects of the CYP 2D6 genotype and cigarette smoking on the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients. Ther Drug Monit 2002; 25: 463-468. 29. Poirier MF i wsp. Prevalence of smoking in psychiatric patients. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 529-537. 30. Van der Bol JM i wsp. Cigarette smoking and irinotekan treatment: Pharmacokinetic interaction and effects on neutropenia. J Clin Oncol 2007; 25: 2719-2726. 31. Hamilton M i wsp. Effects of smoking on the pharmacokinetics of erlotinib. Clin Cancer Res 2006; 12: 2166- 2171. 32. Hooten MW. The effects of smoking status on opioid tapering among patients with chronic pain. Anesth Analg 2009; 108: 308-315. 33. Lidegaard Ø. Smoking and use of oral contraceptives: Impact on thrombotic diseases. Am J Obstet Gynecol 1999; 180: 357-363. 34. Schiff I. Oral contraceptives and smoking, current considerations: Recommendations of a consensus panel. Am J Obstet Gynecol 1999; 180: 383-384. 35. Stańczak A, Lewgowd W. Interakcje leków ze składnikami dymu tytoniowego. Cz. II. Bromat Chem Toksykol 2009; 42: 97-103. 36. Florek E, Piekoszewski W. Interakcje leków z dymem tytoniowym. Katedra i Zakład Toksykologii Akademia Medyczna im. Karola Marcinkowskiego w Poznaniu, Poznań 2006. 37. Schaffer SD, Yoon S, Zadezensky I. A review of smoking cessation: potentially risky effects on prescribed medications. J Clin Nurs 2009; 18: 1533-1540. 38. Zevin S, Benowitz NL. Drug interactions with tobacco smoking. Clin Pharmacokinet 1999; 36: 425-438. 39. Kroon LA. Drug interactions and smoking: Raising awareness for acute and critical care providers. Crit Care Nurs Clin N Am 2006; 18: 53-62. 40. Gritz ER, Dresler C, Sarna L. Smoking, The missing drug interaction in clinical trials: Ignoring the obvious. Cancer Epidemiol Biomarkers Prev 2005; 14: 2287- 2293. 41. Jensen EX i wsp. Impact of chronic cigarette smoking on body composition and fuel metabolism. Journal Clin Endocrinol Metab 1995; 80: 2181-2185. 42. Braganza G, Chaudhuri R, Thomson NC. Treating patients with respiratory disease who smoke. Ther Adv Respir Dis 2008; 2: 95-107. 43. Yamasaki A i wsp. Environmental tobacco smoke and its effect on the symptoms and medication in children with asthma. Int J Environ Health Res 2009; 19: 97- 108. 44. Jusko WJ. Role of tobacco smoking in pharmacokinetics. J Pharmacokinet Biopharm 1978; 6: 7-39. 45. Apud JA, Egan MF, Wyatt RJ. Effects of smoking during antipsychotic withdrawal in patients with chronic schizophrenia. Schizophr Res 2000; 46: 119-127. 46. Haslemo T. i wsp. The effect of variable cigarette consumption on the interaction with clozapine and olanzapine. Eur J Clin Pharmacol. 2006; 62: 1049-1053. 47. Lowe EJ, Ackman ML. Impact of tobacco smoking cessation on stable clozapine or olanzapine treatment. The Ann Pharmacother 2010; 44: 727-732. 48. Leon J. Atypical antipsychotic dosing: The effect of smoking and caffeine. Psychiat Serv 2004; 55: 491-493. 49. Carrillo J i wsp. Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine. J Clin Psychopharmacol 2003; 23: 119-127. 50. Benowitz NL. Cigarette smoking and the personalization of irinotecan therapy. J Clin Oncol 2007; 25: 2646- 2647. 51. Yousef AM i wsp. Smoking behavior modulates pharmacokinetics of orally administered clopidogrel. J Clin Pharm Ther 2008; 33: 439-449. 52. Backman JT, Schröeder MT, Neuvonen PJ. Effects of gender and moderate smoking on the pharmacokinetics and effects of the CYP1A2 substrate tizanidine. Eur J Clin Pharmacol 2008; 64: 17-24. 53. Benowitz NL, Peng M, Peyton J. Effects of cigarette smoking and carbon monoxide on chlorzoxazone and caffeine metabolism. Clin Pharmacol Ther 2003; 74: 468-474. 58

copyright © 2010 Grupa dr. A. R. Kwiecińskiego ISSN 1425-5073 54. Hukkanen J. i wsp. Effects of nicotine on cytochrome P450 2A6 and 2E1 activities. Br J Clin Pharmacol 2009; 69: 152-159. 55. Roy S. Effects of smoking on prostacyclin formation and platelet aggregation in users of oral contraceptives. Am J Obstet Gynecol 1999; 180: 364-368. 56. Barrett D H i wsp. Trends in oral contraceptive use and cigarette smoking. Arch Fam Med. 1994; 3: 438-443. 57. Crawford E. Oral contraceptive steroid plasma concentrations in smokers and non-smokers. Br Med J 1981; 282: 1829-1830. 58. Paszkowski T, Wrona W. Hormonalna terapia zastępcza u kobiet uzależnionych od dymu tytoniowego. Przegl Menopauz 2005; 4: 68-72. 59. Florek E, Enko J, Piekoszewski W. Papieros i kawa – interakcje farmakokinetyczne nikotyny i kofeiny. Przegl Lek 2009; 66: 866-868. data otrzymania pracy: 22.07.2010 r. data akceptacji do druku: 19.11.2010 r. Adres do korespondencji: dr n. farm. Maciej Łukasz Goniewicz Zakład Chemii Ogólnej i Nieorganicznej Wydział Farmaceutyczny z Oddziałem Medycyny Laboratoryjnej Śląski Uniwersytet Medyczny w Katowicach ul. Jagiellońska 4 41-200 Sosnowiec Tel./fax: +48 32 364 15 68 e-mail: mgoniewicz@sum.edu.pl 59

copyright © 2010 Grupa dr. A. R. Kwiecińskiego ISSN 1425-5073<br />

54. Hukkanen J. i wsp. Effects of nicotine on cytochrome<br />

P450 2A6 and 2E1 activities. Br J Clin Pharmacol 2009;<br />

69: 152-159.<br />

55. Roy S. Effects of smoking on prostacyclin formation<br />

and platelet aggregation in users of oral contraceptives.<br />

Am J Obstet Gynecol 1999; 180: 364-368.<br />

56. Barrett D H i wsp. Trends in oral contraceptive use<br />

and cigarette smoking. Arch Fam Med. 1994; 3:<br />

438-443.<br />

57. Crawford E. Oral contraceptive steroid plasma concentrations<br />

in smokers and non-smokers. Br Med J 1981;<br />

282: 1829-1830.<br />

58. Paszkowski T, Wrona W. Hormonalna terapia zastępcza<br />

u kobiet uzależnionych od dymu tytoniowego. Przegl<br />

Menopauz 2005; 4: 68-72.<br />

59. Florek E, Enko J, Piekoszewski W. Papieros i kawa – interakcje<br />

farmakokinetyczne nikotyny i kofeiny. Przegl<br />

Lek 2009; 66: 866-868.<br />

data otrzymania pracy: 22.07.2010 r.<br />

data akceptacji do druku: 19.11.2010 r.<br />

Adres do korespondencji:<br />

dr n. farm. Maciej Łukasz Goniewicz<br />

Zakład Chemii Ogólnej i Nieorganicznej<br />

Wydział <strong>Farmaceutyczny</strong> z Oddziałem Medycyny Laboratoryjnej<br />

Śląski Uniwersytet Medyczny w Katowicach<br />

ul. Jagiellońska 4<br />

41-200 Sosnowiec<br />

Tel./fax: +48 32 364 15 68<br />

e-mail: mgoniewicz@sum.edu.pl<br />

59

logo

products

Resources

Company

Terms of service
Privacy policy
Cookie policy
Cookie settings
Imprint
Change language
Made with love in Switzerland
© 2024 Yumpu.com all rights reserved

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!